Beijing Winsunny Pharmaceutical CO.LTD
Beijing Foyou Pharma CO.,LTD engages in the research and development, production, and sale of pharmaceutical preparations and medical devices China and internationally. The company provides chemical drugs and traditional chinese medicines. Its products used in cardiovascular kind, chronic kidney disease, skin disease, digestive system, diabetes, neuropsychiatric system kind, mental nervous system… Read more
Beijing Winsunny Pharmaceutical CO.LTD (601089) - Total Liabilities
Latest total liabilities as of June 2025: CN¥1.10 Billion CNY
Based on the latest financial reports, Beijing Winsunny Pharmaceutical CO.LTD (601089) has total liabilities worth CN¥1.10 Billion CNY as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Beijing Winsunny Pharmaceutical CO.LTD - Total Liabilities Trend (2020–2024)
This chart illustrates how Beijing Winsunny Pharmaceutical CO.LTD's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Beijing Winsunny Pharmaceutical CO.LTD Competitors by Total Liabilities
The table below lists competitors of Beijing Winsunny Pharmaceutical CO.LTD ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Movado Group Inc
NYSE:MOV
|
USA | $252.01 Million |
|
Veradigm Inc.
NASDAQ:MDRX
|
USA | $513.64 Million |
|
GSR III Acquisition Corp. Unit
NASDAQ:GSRTU
|
USA | $10.07 Million |
|
Hangzhou Star Shuaier Electric Appliance Co Ltd
SHE:002860
|
China | CN¥1.33 Billion |
|
Shenzhen Lifotronic Technology Co
SHG:688389
|
China | CN¥549.45 Million |
|
Yuhuan CNC Machine Tool Co Ltd
SHE:002903
|
China | CN¥396.62 Million |
|
Agriculture & Natural Solutions Acquisition Corporation Class A Ordinary Shares
NASDAQ:ANSC
|
USA | $27.31 Million |
|
Titan International Inc
NYSE:TWI
|
USA | $1.15 Billion |
Liability Composition Analysis (2020–2024)
This chart breaks down Beijing Winsunny Pharmaceutical CO.LTD's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.73 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.31 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.23 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Beijing Winsunny Pharmaceutical CO.LTD's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Beijing Winsunny Pharmaceutical CO.LTD (2020–2024)
The table below shows the annual total liabilities of Beijing Winsunny Pharmaceutical CO.LTD from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥1.26 Billion | +17.67% |
| 2023-12-31 | CN¥1.07 Billion | -6.28% |
| 2022-12-31 | CN¥1.14 Billion | +21.87% |
| 2021-12-31 | CN¥937.86 Million | +32.28% |
| 2020-12-31 | CN¥709.01 Million | -- |